BIOMERICA, INC. Files 8-K: Director & Officer Changes
Ticker: BMRA · Form: 8-K · Filed: Oct 8, 2025 · CIK: 73290
Sentiment: neutral
Topics: director-changes, officer-changes, compensation
TL;DR
BIOMERICA 8-K: Board and exec comp changes filed Oct 7, 2025.
AI Summary
On October 7, 2025, BIOMERICA, INC. filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The filing also includes information on financial statements and exhibits, along with a Regulation FD disclosure. Specific details regarding the nature of these changes, including names of individuals and exact compensation figures, are not provided in this excerpt.
Why It Matters
This filing indicates potential shifts in the company's leadership and compensation structure, which could impact strategic direction and investor confidence.
Risk Assessment
Risk Level: medium — Changes in directors and officers, along with compensation adjustments, can signal internal shifts that may affect future performance.
Key Players & Entities
- BIOMERICA, INC. (company) — Registrant
- October 7, 2025 (date) — Date of earliest event reported
FAQ
What specific changes were made to the board of directors?
The filing indicates changes in directors, but the specific names and details of these changes are not provided in the excerpt.
What are the details of the new compensatory arrangements for officers?
The filing mentions compensatory arrangements of certain officers, but the specific details, including dollar amounts or terms, are not included in this excerpt.
What is the significance of the Regulation FD disclosure?
The Regulation FD disclosure indicates that the company is providing material non-public information in a manner that ensures broad public dissemination, as required by SEC rules.
What financial statements or exhibits are included with this filing?
The filing states that financial statements and exhibits are included, but the specific list or content is not detailed in the provided excerpt.
When was BIOMERICA, INC. incorporated and in what jurisdiction?
BIOMERICA, INC. was incorporated in Delaware.
Filing Stats: 1,065 words · 4 min read · ~4 pages · Grade level 10.7 · Accepted 2025-10-08 08:19:33
Key Financial Figures
- $0.08 B — ch registered Common Stock, par value $0.08 BMRA Nasdaq Capital Market Indicate
- $45,000 — will receive an annualized cash fee of $45,000 (paid quarterly). Mr. Huff will not rec
Filing Documents
- form8-k.htm (8-K) — 47KB
- ex99-1.htm (EX-99.1) — 21KB
- ex99-1_001.jpg (GRAPHIC) — 14KB
- 0001493152-25-017363.txt ( ) — 255KB
- bmra-20251007.xsd (EX-101.SCH) — 3KB
- bmra-20251007_lab.xml (EX-101.LAB) — 33KB
- bmra-20251007_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
From the Filing
UNITED SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 7, 2025 BIOMERICA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37863 95-2645573 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 17571 Von Karman Ave. Irvine , California 92614 (Address of Principal Executive Offices) (Zip Code) Registrant's telephone number, including area code: (949) 645-2111 Not Applicable (Former name or former address if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol Name of each exchange on which registered Common Stock, par value $0.08 BMRA Nasdaq Capital Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Effective October 7, 2025, the Board of Directors (the "Board") of Biomerica, Inc. (the "Company") elected to increase the size of the Board from five directors to six directors and appointed Mr. Gary Huff to serve as an independent member of the Board, effective immediately. The new member of the Board was appointed to fill the vacancy on the Board created by the increase of the size of the Board. The Board has determined that Mr. Huff is an independent director within the meaning of Nasdaq Rule 5605 and the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The Board also appointed Mr. Huff to serve as a member of the Company's Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee. Mr. Huff will stand for election to the Board at our 2025 Annual Meeting of Stockholders (the "2025 Annual Meeting"). Mr. Huff, a distinguished leader in the healthcare industry, has over 35 years of experience in the laboratory field. As the co-founder of Starboost Health and the founder and president of Take Charge, LLC, he is highly regarded for his strategic advisory services, which he provides to private equity firms, hospitals, health systems, and independent clinical and anatomic pathology laboratories. Notably, he is well respected by hospital and health system executives for guiding them through the laboratory outreach asset sales process. Mr. Huff has held several executive roles, including Chief Executive Officer of LabCorp Diagnostics, Chief Executive Officer of Baylor Genetics, and Chief Operating Officer of Solstas Lab Partners. His background includes working with Fortune 500 companies and leading various types of laboratories, from public and private equity-backed organizations to health system-owned entities. Mr. Huff's extensive and successful leadership experience in large clinical labs, private equity, and academic institutions gives him a unique industry perspective. His service on various healthcare boards and his reputation for guiding organizations through significant challenges highlight his ability to provide strategic and innovative leadership. In connection with his appointment to the Board, Mr. Huff will receive an annualized cash fee of $45,000 (paid quarterly). Mr. Huff will not receive any equity-based compensation in connection with his appointment. Mr. Huff does not have a family relationship with any of the executive officers or directors of the Company. There are no arrangements or understandings between Mr. Huff and any other persons pursuant to which he was selected as a director, and there are no transactions in which he has an interest requiring disclosure under Item 404(a) of Regulation S-K. Additionally, on October 7, 2025, Dr. Jane Emerson, a member of the Board, communicated to the Board tha